

Proveca Ltd.
No. 1 Spinningfields
Quay Street
Manchester
M3 3JE
UK

Tel: +44 (0) 0161 468 2627 Email: info@proveca.com

## Proveca Ltd. Transfer of Value Disclosure 2023 Methodological Note

## **Introduction**

Proveca Ltd. engages UK healthcare professionals (HCPs), other relevant decision makers (ORDMs), healthcare organisations (HCOs) and patients' organisations to obtain independent and expert advice to ensure high standards of patient care. Such engagements include, but are not limited to research and development, educational and training events, advisory board meetings and attendance at conferences including promotional activities.

Proveca Ltd. has agreed to comply with the ABPI Code of Practice to document and publicly disclose payments or other Transfers of Value (ToV) made directly or indirectly to HCPs, ORDMs and HCOs. This note describes Proveca Ltd's method of disclosure of ToV for 2023, in accordance with the requirements of the ABPI code.

In 2023, we reviewed all payments made by Proveca to external sources. The relevant payments for disclosure, as per the ABPI 2021 Code of Practice, were identified. These payments and all the invoices for these payments were reviewed and added to the Disclosure UK spreadsheet provided. The spreadsheet was checked for validation prior to submission.

With regards to contracts, the ToV in this disclosure only relates to contracts for one-off services. There were no long-standing agreements with HCPs.

## **Currency aspects and Value Added Tax (VAT)**

All disclosures of ToV made to UK HCPs, HCOs, and/or ORDMs in 2023 are declared in Pound Sterling (£). Where the original payment was made in another currency (for example Euro(€)), the sum was converted to Pound Sterling (£) at the exchange rate prevailing at the time of the original payment.

Payments made to HCOs, including R&D payments, are declared in Pound Sterling (£) and values disclosed do not include VAT.

Payments made to HCPs are declared in Pound Sterling (£) and the values disclosed are the full payment for fees and expenses with no tax added.

Date of preparation: March 2024

**Lawful basis for Disclosure** 

In 2022, Proveca Ltd took the decision to move from 'Consent' to 'Legitimate Interests' as their

lawful basis for Disclosure of ToV. HCPs are not asked for formal consent to have their data published publicly and are informed by Proveca Ltd that their data will be individually disclosed. Individuals have the right to raise objections to public publication of their ToV; no

objections were received by Proveca Ltd in 2023.

"The ABPI champions companies' use of Legitimate Interests for Disclosure UK as a strong

commitment to ethical and transparent collaboration. This position is supported by

stakeholders across the UK life-sciences sector" (ABPI, 2023).

**Categories of Disclosure** 

**Donations and Grants to HCOs** 

Donations and grants are funds, benefits-in-kind or services freely given for the purpose of

supporting healthcare, scientific research or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods or services to the benefit of

the pharmaceutical company in return. Donations and grants to individuals are prohibited.

In general, donations are physical items, services or benefits-in-kind which may be offered or

requested. Grants are the provision of funds.

**Contribution to costs of Events** 

Sponsorship means a contribution, financial or otherwise, in whole or in part provided by or

on behalf of a company, towards an activity (including an event/meeting or material) performed, organised, created etc by a HCO, patient organisation or other independent

organisation.

Support is the provision of a financial contribution, in whole or in part, whether paid directly

or indirectly to individual HCPs or ORDMs to attend events/meetings, and is limited to travel,

subsistence (food and drink), accommodation and genuine registration fees extended in

connection with events/meetings.

**Contracted Services** 

Contracted services provided by HCPs, ORDMs, and HCOs include services such as speaking at

and chairing meetings, involvement in medical/scientific studies, clinical trials or training

services, writing articles and/or publications, participation at advisory board meetings, and

Date of preparation: March 2024

participation in market research where such participation may involve remuneration and/or hospitality. Fees for services reflect fair market value for the services provided. Expenses are limited to travel, subsistence (food and drink), and accommodation associated with the

provision of the contracted service.

**Non-monetary ToV** 

Disclosure of non-monetary ToV is made at the equivalent value in monetary terms. No nonmonetary ToV to patient organisations took place for the reporting period.

There were no Collaborative Working agreements in 2023.

**Collaborative Working ToV (including Joint Working)** 

Research and Development ToV

ToV to HCPs and HCOs related to Research and Development were disclosed in an aggregate

fashion and as required by Clause 1.20 of the ABPI Code of Practice.

**Excluded transfer of values** 

No transfer of values were excluded for the reporting period.

The Association of the British Pharmaceutical Industry. 16 March 2023. What is Legitimate Interests? [Online]. ABPI. Available from: https://www.abpi.org.uk/publications/what-islegitimate-interests/ [Accessed 12 March 2023].

Date of preparation: March 2024